Increased Plasminogen Activator Inhibitor-1 and Vasculopathy
1999; Lippincott Williams & Wilkins; Volume: 99; Issue: 19 Linguagem: Inglês
10.1161/01.cir.99.19.2496
ISSN1524-4539
Autores Tópico(s)Blood Coagulation and Thrombosis Mechanisms
ResumoHomeCirculationVol. 99, No. 19Increased Plasminogen Activator Inhibitor-1 and Vasculopathy Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBIncreased Plasminogen Activator Inhibitor-1 and Vasculopathy A Reconcilable Paradox Burton E. Sobel Burton E. SobelBurton E. Sobel From the Department of Medicine, The University of Vermont College of Medicine, Burlington,Vt. Originally published18 May 1999https://doi.org/10.1161/01.CIR.99.19.2496Circulation. 1999;99:2496–2498A ParadoxAltered activities of plasminogen activator (PA) and plasminogen activator inhibitor type-1 (PAI-1) in vessels are associated with atherosclerosis.12345 However, their impacts on the inferred pathogenetic mechanisms seem contradictory. Proteolysis mediated by PAs contributes to vascular smooth muscle migration, neointimalization, and activation of matrix metalloproteases (MMPs) that precipitate plaque rupture.678 Conversely, PAI-1 is increased in blood and vessel walls with type 2 diabetes mellitus, yet the incidence of acute coronary syndromes (ACS) precipitated by plaque rupture is extraordinarily high.9101112Atherogenesis entails13 the following steps: activation of monocytes/macrophages14 by oxidized LDL15 and expression of monocyte chemotactic activating factors such as leukocyte CXCR-2 and its homologs and ligands16 ; their migration into the neointima and elaboration of MMPs7 ; consequent fragmentation of the internal elastic lamina; accumulation of lipid; migration and subsequent proliferation of vascular smooth muscle cells (VSMCs)151718 ; and proliferation of VSMCs that form largely cellular plaques that can obstruct flow. Until recently, such lesions were thought to account not only for effort-induced clinically stable angina pectoris but also for ACS including unstable angina, Q- and non–Q-wave myocardial infarction (MI), and sudden cardiac death.Falk19 and Davies et al20 identified an important dichotomy. They found that plaques associated with ACS differ strikingly from those typically associated with stable angina21 by being lipid laden, remarkably acellular, and covered by thin fibrous caps prone to rupture. Activated macrophages in the shoulder regions of such plaques precipitate plaque rupture mediated by activation of MMPs.7 Rupture precipitates intramural hemorrhage and thrombosis, luminal compression and obstruction, and ACS.PAs and Migration of VSMCsNeointimal migration of VSMCs depends on surface expression of PAs.6222324 Plasmin generated from plasminogen in the extracellular matrix activates MMPs and facilitates migration. Thus, proteolysis is pivotal in initiation of plaque formation (activation of monocytes/macrophages), migration of VSMCs (surface proteo[fibrino]lysis), and rupture of complex plaques precipitating ACS.This paradigm accounts for the precipitous decrease in incidence of ACS (by 25% to 80%) after lipid lowering despite only trivial diminution of obstruction (0.054% to 2.2%).2526 The dichotomy reflects plaques being rendered more stable by reduction of the ratio of core lipid to cellular elements.27 The paradigm accounts also for decreased ACS seen with the use of anti-inflammatory, antiplatelet, and anticoagulant agents.2829Resolution of the ParadoxOne condition underlying ACS,30 insulin resistance with or without impaired glucose tolerance or frank type 2 diabetes mellitus, is characterized by inhibition of proteolysis.103132 Thus, PAI-1 is increased in blood32 and in coronary plaques in patients with type 2 diabetes.10 Insulin increases PAI-1 protein and mRNA in vessel walls and PAI-1 protein in blood.3334 Hyperinsulinemia induced in normal subjects increases blood PAI-1.35 Although it is obvious that increased PAI-1 can limit fibrinolysis and potentiate thrombosis that precipitates ACS, it is not obvious how increased PAI-1 and decreased proteo(fibrino)lysis in vessel walls can exacerbate vasculopathy, because proteolysis is so pivotal in atherogenesis. Furthermore, plasminogen knockout mice36 exhibit decreased migration of VSMCs after electrical injury to vessels that has been interpreted as indicative of protection against vasculopathy. In addition, in PAI-1–overproducing mice, VSMC migration is attenuated,37 and VSMC accumulation is reduced at sites of injury.35The conventional wisdom holds that (1) accumulation of VSMCs and formation of a thick, cellular neointima is "bad" (a hallmark of "malignant" atherosclerotic lesions), and (2) inhibition of migration of VSMCs (and subsequent proliferation) is "good." However, this view may be wrong.In evolving atheroma, elevation of PAI-1 is marked.10 PAI-1 is prominent in early fatty lesions in nondiabetic subjects38 and in complex atheroma known to predispose to ACS in diabetic subjects.10 As in PAI-1–overproducing mice,37 the increased PAI-1 should inhibit VSMC migration, subsequent proliferation, and accumulation. However, such inhibition may be bad if it predisposes to formation of acellular plaques. By analogy, inhibition of scar formation makes wound healing "look better" but predisposes to dehiscence; inhibition of granuloma formation with mycobacterial infection makes the lung "look better" but predisposes to death. Thus, inhibition of VSMC migration may make evolving atheroma look better yet predispose to formation of preponderantly acellular plaques particularly prone to rupture.In fact, observations in genetically modified mice3637 are consistent with this interpretation. The response to injury is impaired migration of VSMCs and a disproportionate decrease in the ratio of VSMCs to matrix and fibrous tissue. These findings may in fact reflect an impaired response to injury that sets the stage for the thin-walled aneurysms seen rather than protection against vasculopathy. Observations in patients with hyperinsulinemia and type 2 diabetes are consistent with this view.10 The increased level of PAI-1 in atheroma and in vessel walls appears likely to potentiate formation of atheroma plaques with lipid-laden cores and thin fibrous caps—plaques particularly prone to rupture. This would account for the high incidence of ACS and the adverse response to angioplasty (4-fold increase in 5-year mortality to 35%).39Construing inhibition of migration of VSMCs as deleterious and migration as protective requires a novel perspective. Changing one's mind-set is analogous, in a sense, to shifting from 1 perceived element to another in an Esher drawing (Figure).Clinical ImplicationsIf the proposed views are correct, inhibition of augmented vessel-wall PAI-1 expression should lead to favorable changes in composition of atherosclerotic plaques that evolve. Increased degradation and decreased accumulation of matrix and robust migration of VSMCs into developing lesions can be anticipated. Thus, a decreased ratio of lipid to VSMCs that renders plaques less prone to rupture would be expected. Similarly, reduced PAI-1 in vessel walls should decrease the incidence of ACS. We have found that thiazolidinediones (insulin sensitizers) decrease PAI-1 in blood in hyperinsulinemic subjects.40 Favorable changes in carotid intimal-medial thickness consistent with reduction of lipid content have been observed as well in a preliminary study.41Atherogenesis is multifactorial. Increased PAI-1 is certainly not its proximate cause. However, increased PAI-1 may predispose to formation of plaques with high lipid-to-VSMC ratios as a result of decreased VSMC migration. Such plaques are particularly prone to rupture and to precipitate ACS. Thus, suppression of PAI-1 gene expression is an attractive pharmacological target.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.Download figureDownload PowerPoint Figure 1. Esher's drawing "Fish/Horse," drawn at Bearn, France, July 1967. Reprinted with permission (Esher MC. In: Schattschneider D, compiler. Visions of Symmetry. New York, NY: WH Freeman & Co; 1998:223).FootnotesCorrespondence to Dr Burton E. Sobel, Department of Medicine, The University of Vermont College of Medicine, Colchester Research Facility, 55A S Park Dr, Colchester, VT 05446. E-mail [email protected] References 1 Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med.1985; 313:1557–1563.CrossrefMedlineGoogle Scholar2 Schneider DJ, Ricci MA, Taatjes DJ, Baumann PQ, Reese JC, Leavitt BJ, Absher PM, Sobel BE. Changes in arterial expression of fibrinolytic system proteins in atherogenesis. Arterioscler Thromb Vasc Biol.1997; 17:3294–3301.CrossrefMedlineGoogle Scholar3 Tipping PG, Davenport P, Gallicchio M, Filonzi EL, Apostolopoulos J, Wojta J. Atheromatous plaque macrophages produce plasminogen activator inhibitor type-1 and stimulate its production by endothelial cells and vascular smooth muscle cells. Am J Pathol.1993; 143:875–885.MedlineGoogle Scholar4 Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A.1992; 89:6998–7002.CrossrefMedlineGoogle Scholar5 Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachman F, Kruithof EKO. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb.1993; 13:1090–1100.CrossrefMedlineGoogle Scholar6 Clowes AW, Clowes MM, Au YP, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res.1990; 67:61–67.CrossrefMedlineGoogle Scholar7 Libby P. Molecular bases of the acute coronary syndromes. Circulation.1995; 91:2844–2855.CrossrefMedlineGoogle Scholar8 He CS, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ, Goldberg GI. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci U S A.1989; 86:2632–2636.CrossrefMedlineGoogle Scholar9 Loskutoff DJ, van Aken BE, Seiffert D. Abnormalities in the fibrinolytic system of the vascular wall associated with atherosclerosis. Ann N Y Acad Sci.1995; 748:177–183.MedlineGoogle Scholar10 Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H. Increased plasminogen activator inhibitor type-1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation.1998; 97:2213–2221.CrossrefMedlineGoogle Scholar11 Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis.1988; 8:68–72.LinkGoogle Scholar12 Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism.1986; 35:250–253.CrossrefMedlineGoogle Scholar13 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med.1992; 326:242–250.CrossrefMedlineGoogle Scholar14 Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med.1986; 314:488–500.CrossrefMedlineGoogle Scholar15 Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med.1989; 320:915–924.CrossrefMedlineGoogle Scholar16 Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest.1998; 101:353–363.CrossrefMedlineGoogle Scholar17 Aqel NM, Ball RY, Waldmann H, Mitchinson MJ. Monocytic origin of foam cells in human atherosclerotic plaques. Atherosclerosis.1984; 53:265–271.CrossrefMedlineGoogle Scholar18 Ip HJ, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol.1990; 15:1667–1687.CrossrefMedlineGoogle Scholar19 Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation.1985; 71:699–708.CrossrefMedlineGoogle Scholar20 Davies MJ, Bland MJ, Hangartner WR, Angelini A, Thomas AC. Factors influencing the presence or absence of acute coronary thrombi in sudden ischemic death. Eur Heart J.1989; 10:203–208.CrossrefMedlineGoogle Scholar21 Falk E. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol.1989; 63:114E–120E.CrossrefMedlineGoogle Scholar22 Campbell GR, Campbell JH, Manderson JA, Horrigan S, Rennick RE. Arterial smooth muscle: a multifunctional mesenchymal cell. Arch Pathol Lab Med.1988; 112:977–986.MedlineGoogle Scholar23 Clowes AW, Clowes MM, Fingerle J, Reidy MA. Regulation of smooth muscle cell growth in injured artery. J Cardiovasc Pharmacol. 1989;14(suppl 6):S12–S15.Google Scholar24 Noda-Heiny H, Sobel BE. Vascular smooth muscle cell migration mediated by thrombin and urokinase receptor. Am J Physiol.1995; 268:C1105–C1201.Google Scholar25 Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med.1995; 332:512–521.CrossrefMedlineGoogle Scholar26 Fuster V, Gotto AM Jr, Libby P, Loscalzo J, McGill HC. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events: Task force 1: pathogenesis of coronary disease: the biologic role of risk factors. J Am Coll Cardiol.1996; 27:964–976.CrossrefMedlineGoogle Scholar27 Davies MJ, Wolf N, Rowles PM, Pepper J. Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. Br Heart J.1988; 60:459–464.CrossrefMedlineGoogle Scholar28 Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and lose-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk: The Medical Research Council's General Practice Research Framework. Lancet.1998; 351:233–241.CrossrefMedlineGoogle Scholar29 Turpie AGG. Clinical potential of antithrombotic drugs in coronary syndromes. Am J Cardiol.1998; 82:11L–14L.CrossrefMedlineGoogle Scholar30 Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest.1993; 92:141–146.CrossrefMedlineGoogle Scholar31 Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MD, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism.1986; 35:250–253.CrossrefMedlineGoogle Scholar32 McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes.1994; 43:104–109.CrossrefMedlineGoogle Scholar33 Nordt TK, Sawa H, Fujii S, Bode C, Sobel BE. Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type-1 (PAI-1) gene by proinsulin and insulin in vivo. J Mol Cell Cardiol.1998; 30:1535–1543.CrossrefMedlineGoogle Scholar34 Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation.1995; 91:764–770.CrossrefMedlineGoogle Scholar35 Calles-Escandon J, Mirza S, Sobel BE, Schneider DJ. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor type-1 (PAI-1) in blood in normal human subjects. Diabetes.1998; 47:290–293.CrossrefMedlineGoogle Scholar36 Carmeliet P, Moons L, Ploplis V, Plow E, Collen D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest.1997; 99:200–208.CrossrefMedlineGoogle Scholar37 Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, Gerard RD. Inhibitor role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation.1997; 96:3180–3191.CrossrefMedlineGoogle Scholar38 Schneider DJ, Ricci MA, Taatjes DJ, Baumann PQ, Reese JC, Leavitt BJ, Absher M, Sobel BE. Changes in arterial expression of fibrinolytic system proteins in atherogenesis. Arterioscler Thromb Vasc Biol.1997; 17:3294–3301.CrossrefMedlineGoogle Scholar39 BARI Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med.1996; 335:217–225.CrossrefMedlineGoogle Scholar40 Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, Polonsky KS. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab.1997; 82:2108–2116.MedlineGoogle Scholar41 Minamikawa J, Yamauchi M, Inoue D, Koshiyama H. Another potential use of troglitazone in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab.1998; 83:1041–1042.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Gentile A, Magnacca N, Matteis R, Moreno M, Cioffi F, Giacco A, Lanni A, Lange P, Senese R, Goglia F, Silvestri E and Lombardi A (2022) Ablation of uncoupling protein 3 affects interrelated factors leading to lipolysis and insulin resistance in visceral white adipose tissue, The FASEB Journal, 10.1096/fj.202101816RR, 36:5, Online publication date: 1-May-2022. Jiménez-González M, Santiago-Germán D, Castillo-Henkel E, Alvarado-Moreno J, Hernández-Juárez J, Leaños-Miranda A, Majluf-Cruz A and Isordia-Salas I (2021) Identificación de factores de riesgo genéticos asociados a la enfermedad vascular cerebral de tipo isquémico en jóvenes mexicanos, Neurología, 10.1016/j.nrl.2018.01.010, 36:5, (337-345), Online publication date: 1-Jun-2021. KOCA N, AYAR K, BAL Ö and ERSOY C The evaluation of the role of BMI and insulin resistance on inflammatory markers, PAI-1 levels and arterial stiffness in newly diagnosed type 2 diabetes mellitus patients, Minerva Endocrinology, 10.23736/S2724-6507.20.03158-2, 46:1 Jiménez-González M, Santiago-Germán D, Castillo-Henkel E, Alvarado-Moreno J, Hernández-Juárez J, Leaños-Miranda A, Majluf-Cruz A and Isordia-Salas I (2019) Identification of genetic risk factors associated with ischaemic stroke in young Mexican patients, Neurología (English Edition), 10.1016/j.nrleng.2018.01.011, Online publication date: 1-Nov-2019. Basurto Acevedo L, Barrera Hernández S, Fernández Muñoz M, Saucedo García R, Rodríguez Luna A and Martínez Murillo C (2018) An increase in epicardial fat in women is associated with thrombotic risk, Clínica e Investigación en Arteriosclerosis (English Edition), 10.1016/j.artere.2017.10.004, 30:3, (112-117), Online publication date: 1-May-2018. Basurto Acevedo L, Barrera Hernández S, Fernández Muñoz M, Saucedo García R, Rodríguez Luna A and Martínez Murillo C (2018) El incremento de la grasa epicárdica en mujeres se asocia a riesgo trombótico, Clínica e Investigación en Arteriosclerosis, 10.1016/j.arteri.2017.10.004, 30:3, (112-117), Online publication date: 1-May-2018. Goeller M, Achenbach S, Marwan M, Doris M, Cadet S, Commandeur F, Chen X, Slomka P, Gransar H, Cao J, Wong N, Albrecht M, Rozanski A, Tamarappoo B, Berman D and Dey D (2018) Epicardial adipose tissue density and volume are related to subclinical atherosclerosis, inflammation and major adverse cardiac events in asymptomatic subjects, Journal of Cardiovascular Computed Tomography, 10.1016/j.jcct.2017.11.007, 12:1, (67-73), Online publication date: 1-Jan-2018. Aburto-Mejía E, Santiago-Germán D, Martínez-Marino M, María Eugenia Galván-Plata , Almeida-Gutiérrez E, López-Alarcón M, Hernández-Juárez J, Alvarado-Moreno A, Leaños-Miranda A, Majluf-Cruz A and Isordia-Salas I (2017) Hypofibrinolytic State in Subjects with Type 2 Diabetes Mellitus Aggravated by the Metabolic Syndrome before Clinical Manifestations of Atherothrombotic Disease, BioMed Research International, 10.1155/2017/6519704, 2017, (1-9), . Avogaro A (2017) Re: "Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus" by Bayomi et al. (Metab Syndr Relat Disord 2017;15:269–275), Metabolic Syndrome and Related Disorders, 10.1089/met.2017.0070, 15:6, (266-268), Online publication date: 1-Aug-2017. Qureshi T, Goswami S, McClintock C, Ramsey M and Peterson C (2015) Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop, Protein Science, 10.1002/pro.2841, 25:2, (499-510), Online publication date: 1-Feb-2016. Kodaman N, Aldrich M, Sobota R, Asselbergs F, Brown N, Moore J and Williams S (2016) Plasminogen Activator Inhibitor‐1 and Diagnosis of the Metabolic Syndrome in a West African Population, Journal of the American Heart Association, 5:10, Online publication date: 3-Oct-2016. Wajchenberg B and Cohen R (2014) Adipose Tissue and Type 2 Diabetes Mellitus Adipose Tissue and Adipokines in Health and Disease, 10.1007/978-1-62703-770-9_16, (235-248), . Cao Y, Zhang J, Meng X and Wang D (2011) TNF-α induces early growth response gene-1 expression via ERK1/2 activation in endothelial cells, Acta Diabetologica, 10.1007/s00592-010-0248-7, 50:1, (27-31), Online publication date: 1-Feb-2013. Morange P and Alessi M (2017) Thrombosis in central obesity and metabolic syndrome: Mechanisms and epidemiology, Thrombosis and Haemostasis, 10.1160/TH13-01-0075, 110:10, (669-680), . Lovely R, Hossain J, Ramsey J, Komakula V, George D, Farrell D and Balagopal P (2013) Obesity-Related Increased γ′ Fibrinogen Concentration in Children and Its Reduction by a Physical Activity-Based Lifestyle Intervention: A Randomized Controlled Study, The Journal of Pediatrics, 10.1016/j.jpeds.2013.01.004, 163:2, (333-338), Online publication date: 1-Aug-2013. Fortenberry Y (2013) Plasminogen activator inhibitor-1 inhibitors: a patent review (2006 – present), Expert Opinion on Therapeutic Patents, 10.1517/13543776.2013.782393, 23:7, (801-815), Online publication date: 1-Jul-2013. Jeon Y, Kim Y, Lee B, Choi Y, Kim J, Shin J, Rah H, Cha S, Lee W and Kim N (2017) Genetic association of five plasminogen activator inhibitor-1 (PAI-1) polymorphisms and idiopathic recurrent pregnancy loss in Korean women, Thrombosis and Haemostasis, 10.1160/TH13-03-0242, 110:10, (742-750), . Apple F, Goetze J and Jaffe A (2012) Cardiac Function Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 10.1016/B978-1-4160-6164-9.00047-0, (1457-1522), . De la Cruz-Mosso U, Muñoz-Valle J, Salgado-Goytia L, García-Carreón A, Illades-Aguiar B, Castañeda-Saucedo E and Parra-Rojas I (2012) Relationship of metabolic syndrome and its components with -844 G/A and HindIII C/G PAI-1 gene polymorphisms in Mexican children, BMC Pediatrics, 10.1186/1471-2431-12-41, 12:1, Online publication date: 1-Dec-2012. Fatouros I and Mitrakou A (2012) Obesity and Diabetes Obesity, 10.1201/b12085-16, (249-310), Online publication date: 11-May-2012. Kato S, Shimada Y, Friedmann P, Kashan G, Husk G and Bergmann S (2012) Identification of residual risk factors for the development of venous thromboembolism in medical inpatients receiving subcutaneous heparin therapy for prophylaxis, Coronary Artery Disease, 10.1097/MCA.0b013e328352e510, 23:4, (294-297), Online publication date: 1-Jun-2012. (2012) The Endothelium, Cardiovascular Disease, and Therapy Metabolic Syndrome and Cardiovascular Disease, 10.1002/9781118480045.ch14, (409-467), Online publication date: 29-Aug-2012. Schneider D and Sobel B (2012) PAI-1 and Diabetes: A Journey From the Bench to the Bedside, Diabetes Care, 10.2337/dc12-0638, 35:10, (1961-1967), Online publication date: 1-Oct-2012. French C, Zaman A and Sobel B (2011) The Angiotensin Receptor Blocker, Azilsartan Medoxomil (TAK-491), Suppresses Vascular Wall Expression of Plasminogen Activator Inhibitor Type-I Protein Potentially Facilitating the Stabilization of Atherosclerotic Plaques, Journal of Cardiovascular Pharmacology, 10.1097/FJC.0b013e31821dcbea, 58:2, (143-148), Online publication date: 1-Aug-2011. BILLAUD M, ROSS J, GREYSON M, BRUCE A, SEAMAN S, HEBERLEIN K, HAN J, BEST A, PEIRCE S and ISAKSON B (2011) A New Method for In Vivo Visualization of Vessel Remodeling Using a Near-Infrared Dye, Microcirculation, 10.1111/j.1549-8719.2011.00085.x, 18:3, (163-171), Online publication date: 1-Apr-2011. Demyanets S, Huber K and Wojta J (2011) Inflammation and the cardiovascular systemEntzündung und das Herzkreislaufsystem, European Surgery, 10.1007/s10353-011-0607-9, 43:2, (78-89), Online publication date: 1-Apr-2011. Balagopal P, de Ferranti S, Cook S, Daniels S, Gidding S, Hayman L, McCrindle B, Mietus-Snyder M and Steinberger J (2011) Nontraditional Risk Factors and Biomarkers for Cardiovascular Disease: Mechanistic, Research, and Clinical Considerations for Youth, Circulation, 123:23, (2749-2769), Online publication date: 14-Jun-2011. Wexberg P and Weidinger F (2010) Revaskularisation der koronaren Herzerkrankung bei Diabetes mellitusRevascularization of coronary artery disease in diabetes mellitus, Wiener Medizinische Wochenschrift, 10.1007/s10354-010-0746-9, 160:1-2, (40-43), Online publication date: 1-Jan-2010. Miyagawa R, Asakura T, Nakamura T, Okada H, Iwaki S, Sobel B and Fujii S (2010) Increased expression of plasminogen activator inhibitor type-1 (PAI-1) in HEPG2 cells induced by insulin mediated by the 3′-untranslated region of the PAI-1 gene and its pharmacologic implications, Coronary Artery Disease, 10.1097/MCA.0b013e328335790e, 21:3, (144-150), Online publication date: 1-May-2010. Fernández C, del Arco A, Gallardo N, Aguado L, Rodriguez M, Ros M, Carrascosa J, Andrés A and Arribas C (2010) S-resistin inhibits adipocyte differentiation and increases TNFα expression and secretion in 3T3-L1 cells, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 10.1016/j.bbamcr.2010.06.012, 1803:10, (1131-1141), Online publication date: 1-Oct-2010. Bouchard L, Vohl M, Lebel S, Hould F, Marceau P, Bergeron J, Pérusse L and Mauriège P (2010) Contribution of Genetic and Metabolic Syndrome to Omental Adipose Tissue PAI-1 Gene mRNA and Plasma Levels in Obesity, Obesity Surgery, 10.1007/s11695-010-0079-1, 20:4, (492-499), Online publication date: 1-Apr-2010. Singh P, Peterson T, Barber K, Kuniyoshi F, Jensen A, Hoffmann M, Shamsuzzaman A and Somers V (2010) Leptin upregulates the expression of plasminogen activator inhibitor-1 in human vascular endothelial cells, Biochemical and Biophysical Research Communications, 10.1016/j.bbrc.2009.12.158, 392:1, (47-52), Online publication date: 1-Jan-2010. Cesari M, Pahor M and Incalzi R (2010) REVIEW: Plasminogen Activator Inhibitor-1 (PAI-1): A Key Factor Linking Fibrinolysis and Age-Related Subclinical and Clinical Conditions, Cardiovascular Therapeutics, 10.1111/j.1755-5922.2010.00171.x, 28:5, (e72-e91), Online publication date: 1-Oct-2010. Hueb W, Lopes N, Soares P, Gersh B, Lima E, Vieira R, Garzillo C, Garcia R, Pereira A, Strunz C, Meneguetti C, Tsutsui J, Parga J, Lemos P, Hueb A, Ushida A, Maranhão R, Chamone D and Ramires J (2010) Hypotheses, rationale, design, and methods for prognostic evaluation in type 2 diabetic patients with angiographically normal coronary arteries. The MASS IV-DM Trial, BMC Cardiovascular Disorders, 10.1186/1471-2261-10-47, 10:1, Online publication date: 1-Dec-2010. Griffith M, Younk L and Davis S (2010) Visceral Adiposity, Insulin Resistance, and Type 2 Diabetes, American Journal of Lifestyle Medicine, 10.1177/1559827609360959, 4:3, (230-243), Online publication date: 1-May-2010. Wajchenberg B, Nery M, Cunha M and Silva M (2009) Adipose tissue at the crossroads in the development of the metabolic syndrome, inflammation and atherosclerosis, Arquivos Brasileiros de Endocrinologia & Metabologia, 10.1590/S0004-27302009000200005, 53:2, (145-150), Online publication date: 1-Mar-2009. Winkelmann B, von Holt K and Unverdorben M (2009) Smoking and atherosclerotic cardiovascular disease: Part I: Atherosclerotic disease process, Biomarkers in Medicine, 10.2217/bmm.09.32, 3:4, (411-428), Online publication date: 1-Aug-2009. Jaulmes A, Sansilvestri-Morel P, Rolland-Valognes G, Bernhardt F, Gaertner R, Lockhart B, Cordi A, Wierzbicki M, Rupin A and Verbeuren T (2009) Nox4 mediates the expression of plasminogen activator inhibitor-1 via p38 MAPK pathway in cultured human endothelial cells, Thrombosis Research, 10.1016/j.thromres.2009.05.018, 124:4, (439-446), Online publication date: 1-Sep-2009. Singh B, Arora S, Goswami B and Mallika V (2009) Metabolic syndrome: A review of emerging markers and management, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 10.1016/j.dsx.2009.04.012, 3:4, (240-254), Online publication date: 1-Dec-2009. Onalan O, Balta G, Oto A, Kabakci G, Tokgozoglu L, Aytemir K, Altay C, Gurgey A and Nazli N (2007) Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease, Journal of Thrombosis and Thrombolysis, 10.1007/s11239-007-0083-z, 26:3, (211-217)
Referência(s)